Argenx price target raised to $675 from $646 at Oppenheimer

Oppenheimer raised the firm’s price target on Argenx (ARGX) to $675 from $646 and keeps an Outperform rating on the shares after the company announced clinical proof-of-concept in myositis, with subQ efgart yielding statistically significant improvement across all three myositis subtypes being evaluated in Phase 2. While the firm looks forward to seeing detailed results at a future medical meeting, Oppenheimer regards the news as broadening Argenx’s leadership in the autoimmune category.